**Author details**

Chris Drakeley<sup>1</sup> \*, Bronner Gonçalves<sup>1</sup> , Lucy Okell<sup>2</sup> and Hannah Slater<sup>2</sup>

\*Address all correspondence to: chris.drakeley@lshtm.ac.uk

1 Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, UK

[6] Vantaux A, Samreth R, Piv EP, Khim N, Kim S, Berne L, et al. Contribution to malaria transmission of symptomatic and asymptomatic parasite carriers in Cambodia. The

Understanding the Importance of Asymptomatic and Low-Density Infections…

http://dx.doi.org/10.5772/intechopen.77293

143

Journal of Infectious Diseases. 2018;**217**(10):1561-1568. DOI: 10.1093/infdis/jiy060

10.1086/374555

pone.0045542

DOI: 10.1186/s12936-016-1224-7

895. DOI: 10.1038/nri2432

10.1371/journal.pone.0008988

malaria. Parassitologia. 2006;**48**:450-467

2018;**18**(5):565-572. DOI: 10.1016/S1473-3099(18)30046-X

Reviews. 2009;**22**:13-36. DOI: 10.1128/CMR.00025-08

New Guinea. eLife. 2017;**6**:e23708. DOI: 10.7554/eLife.23708

[7] Missinou MA, Lell B, Kremsner PG. Uncommon asymptomatic *Plasmodium falciparum* infections in Gabonese children. Clinical Infectious Diseases. 2003;**36**:1198-1202. DOI:

[8] Felger I, Maire M, Bretscher MT, Falk N, Tiaden A, Sama W, et al. The dynamics of natural *Plasmodium falciparum* infections. PLoS One. 2012;**7**:e45542. DOI: 10.1371/journal.

[9] Landier J, Kajeechiwa L, Thwin MM, Parker DM, Chaumeau V, Wiladphaingern J, et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: A pilot trial in four villages of eastern Myanmar.

[10] Tripura R, Peto TJ, Chalk J, Lee SJ, Sirithiranont P, Nguon C, et al. Persistent *Plasmodium falciparum* and *Plasmodium vivax* infections in a western Cambodian population: Implications for prevention, treatment and elimination strategies. Malaria Journal. 2016;**15**:181.

[11] Nguyen TN, von Seidlein L, Nguyen TV, Truong PN, Hung SD, Pham HT, et al. The persistence and oscillations of submicroscopic *Plasmodium falciparum* and *Plasmodium vivax* infections over time in Vietnam: An open cohort study. The Lancet Infectious Diseases.

[12] Schneider DS, Ayres JS. Two ways to survive infection: What resistance and tolerance can teach us about treating infectious diseases. Nature Reviews. Immunology. 2008;**8**:889-

[13] Kwiatkowski DP, Luoni G. Host genetic factors in resistance and susceptibility to

[14] Carneiro I, Roca-Feltrer A, Griffin JT, Smith L, Tanner M, Schellenberg JA, et al. Agepatterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan Africa: A systematic review and pooled analysis. PLoS One. 2010;**5**:e8988. DOI:

[15] Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clinical Microbiology

[16] Hofmann NE, Karl S, Wampfler R, Kiniboro B, Teliki A, Iga J, et al. The complex relationship of exposure to new *Plasmodium* infections and incidence of clinical malaria in Papua

[17] Gwamaka M, Kurtis JD, Sorensen BE, Holte S, Morrison R, Mutabingwa TK, et al. Iron deficiency protects against severe *Plasmodium falciparum* malaria and death in young

children. Clinical Infectious Diseases. 2012;**54**:1137-1144. DOI: 10.1093/cid/cis010

Wellcome Open Research. 2017;**2**:81. DOI: 10.12688/wellcomeopenres.12240.1

2 Department of Infectious Disease Epidemiology, Imperial College London, UK
